LEADER 01840nam  2200373   450 
001 9910597915403321
005 20230220214134.0
035   $a(CKB)4920000000094882
035   $a(NjHacI)994920000000094882
035   $a(EXLCZ)994920000000094882
100   $a20230220d2018      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aMarine Compounds and Cancer /$fedited by Friedemann Honecker, Sergey A. Dyshlovoy
210  1$aBasel :$cMDPI - Multidisciplinary Digital Publishing Institute,$d2018.
215   $a1 online resource (v, 110 pages)
311   $a3-03842-765-9 
330   $aThe very first marine-derived anticancer drug, Cytarabine (aka Ara-C, Cytosar-U(R)), was approved by the FDA in 1969 for the treatment of leukemia. At the beginning of 2021, the list of approved marine-derived anticancer drugs consists of nine substances, five of which received approval within the last two years, demonstrating the rapid evolution of the field. The current book is a collection of scientific articles related to the exponentially growing field of anticancer marine compounds. These articles cover the whole field, from agents with cancer-preventive activity, to novel and previously characterized compounds with anticancer activity, both in vitro and in vivo, as well as the latest status of compounds under clinical development.
606   $aCancer$xRadiotherapy
606   $aMarine toxins
615  0$aCancer$xRadiotherapy.
615  0$aMarine toxins.
676   $a615.945
702   $aHonecker$b Friedemann
702   $aDyshlovoy$b Sergey A.
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910597915403321
996   $aMarine Compounds and Cancer$92947621
997   $aUNINA